Journal ArticleOphthalmology · August 2024
PURPOSE: To evaluate 2-year efficacy, durability, and safety of the bispecific antibody faricimab, which inhibits both angiopoietin-2 and VEGF-A. DESIGN: TENAYA (ClinicalTrials.gov identifier, NCT03823287) and LUCERNE (ClinicalTrials.gov identifier, NCT038 ...
Full textLink to itemCite
Journal ArticleEye (Lond) · July 2024
OBJECTIVE: To evaluate the safety and efficacy of BI 1467335 in patients with non-proliferative diabetic retinopathy (NPDR). METHODS: ROBIN is a Phase IIa, double-masked, randomised, placebo-controlled study (NCT03238963). Patients with NPDR and without ce ...
Full textLink to itemCite
Journal ArticleOphthalmology · June 2024
PURPOSE: To evaluate the 2-year efficacy, durability, and safety of dual angiopoietin-2 and vascular endothelial growth factor (VEGF) A pathway inhibition with intravitreal faricimab according to a personalized treat-and-extend (T&E)-based regimen with up ...
Full textLink to itemCite
Journal ArticleOphthalmol Retina · April 2024
OBJECTIVE: To assess the feasibility of daily Home OCT imaging among patients with neovascular age-related macular degeneration (nAMD). DESIGN: Prospective observational study. PARTICIPANTS: Participants with ≥ 1 eye with previously untreated nAMD and visu ...
Full textLink to itemCite
Journal ArticleLancet · October 21, 2023
BACKGROUND: Geographic atrophy is a leading cause of progressive, irreversible vision loss. The objectives of OAKS and DERBY were to assess the efficacy and safety of pegcetacoplan compared with sham treatment in patients with geographic atrophy. METHODS: ...
Full textLink to itemCite
Journal ArticleOphthalmol Retina · July 2023
PURPOSE: To evaluate the safety and efficacy of repeat injections of Brimonidine Drug Delivery System (Brimo DDS) Generation 2 (Gen 2) containing 400-μg brimonidine in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD ...
Full textLink to itemCite
Journal ArticleOphthalmology · June 2023
PURPOSE: Neovascular (wet) age-related macular degeneration (nAMD) is driven by VEGFs A, C, and D, which promote angiogenesis and vascular permeability. Intravitreal injections of anti-VEGF-A drugs are the standard of care, but these do not inhibit VEGF-C ...
Full textLink to itemCite
Journal ArticlePLoS One · 2023
BACKGROUND: Vitreous hemorrhage from proliferative diabetic retinopathy can cause severe vision loss. DRCR Retina Network Protocol AB was a randomized clinical trial comparing intravitreal aflibercept versus vitrectomy with panretinal photocoagulation and ...
Full textLink to itemCite
Journal ArticleJAMA Ophthalmol · October 1, 2022
IMPORTANCE: Presence of predominantly peripheral diabetic retinopathy (DR) lesions on ultra-widefield fluorescein angiography (UWF-FA) was associated with greater risk of DR worsening or treatment over 4 years. Whether baseline retinal nonperfusion assessm ...
Full textLink to itemCite
Journal ArticleJAMA Ophthalmol · October 1, 2022
IMPORTANCE: Ultra-widefield (UWF) imaging improves the ability to identify peripheral diabetic retinopathy (DR) lesions compared with standard imaging. Whether detection of predominantly peripheral lesions (PPLs) better predicts rates of disease worsening ...
Full textLink to itemCite
Journal ArticleLancet · February 19, 2022
BACKGROUND: Faricimab is a bispecific antibody that acts through dual inhibition of both angiopoietin-2 and vascular endothelial growth factor A. We report primary results of two phase 3 trials evaluating intravitreal faricimab with extension up to every 1 ...
Full textLink to itemCite
Journal ArticleLancet · February 19, 2022
BACKGROUND: To reduce treatment burden and optimise patient outcomes in diabetic macular oedema, we present 1-year results from two phase 3 trials of faricimab, a novel angiopoietin-2 and vascular endothelial growth factor-A bispecific antibody. METHODS: Y ...
Full textLink to itemCite
Journal ArticleJAMA Ophthalmol · July 1, 2021
IMPORTANCE: The role of anti-vascular endothelial growth factor injections for the management of nonproliferative diabetic retinopathy (NPDR) without center-involved diabetic macular edema (CI-DME) has not been clearly established. OBJECTIVE: To determine ...
Full textLink to itemCite
Journal ArticleJAMA Ophthalmol · July 1, 2021
IMPORTANCE: Although there were no differences in mean visual acuity (VA) over 24 weeks after vitrectomy with panretinal photocoagulation (PRP) vs aflibercept in a randomized clinical trial among eyes with vitreous hemorrhage due to proliferative diabetic ...
Full textLink to itemCite
Journal ArticleJAMA · December 15, 2020
IMPORTANCE: Vitreous hemorrhage from proliferative diabetic retinopathy can cause loss of vision. The best management approach is unknown. OBJECTIVE: To compare initial treatment with intravitreous aflibercept vs vitrectomy with panretinal photocoagulation ...
Full textLink to itemCite
Journal ArticleOphthalmology · September 2020
PURPOSE: Assess follow-up treatment and clinical outcomes at 5 years in eyes initially treated with anti-VEGF therapy for center-involved diabetic macular edema (CI-DME) in a 2-year randomized clinical trial. DESIGN: Multicenter cohort study. PARTICIPANTS: ...
Full textLink to itemCite
Journal ArticleOphthalmol Retina · March 2020
PURPOSE: OPT-302 is a novel inhibitor of vascular endothelial growth factor (VEGF)-C and VEGF-D. A phase 1 trial assessed the safety of intravitreal OPT-302 as monotherapy or combined with ranibizumab (Lucentis; Genentech, South San Francisco, CA) in patie ...
Full textLink to itemCite
Journal ArticleOphthalmol Retina · January 2020
PURPOSE: To analyze best-corrected visual acuity (BCVA) outcomes after anti-vascular endothelial growth factor (VEGF) treatment for neovascular age-related macular degeneration (AMD). DESIGN: Prospective cohort study of participants enrolled in a clinical ...
Full textLink to itemCite
Journal ArticleAm J Ophthalmol Case Rep · September 2019
PURPOSE: To discuss two striking cases of ophthalmomyiasis interna posterior, in which the larval stage of a botfly is found in the posterior segment. OBSERVATIONS: In the first case, the subretinal maggot is alive and found to be migrating under the retin ...
Full textLink to itemCite
Journal ArticleJAMA · May 21, 2019
IMPORTANCE: Intravitreous injections of antivascular endothelial growth factor agents are effective for treating diabetic macular edema (DME) involving the center of the macula (center-involved DME [CI-DME]) with visual acuity impairment (20/32 or worse). ...
Full textLink to itemCite
Journal ArticleOphthalmology · February 2019
PURPOSE: To investigate the natural history and genetic associations of drusenoid pigment epithelial detachment (DPED) associated with age-related macular degeneration (AMD). DESIGN: Retrospective analysis of a prospective cohort study. PARTICIPANTS: Of th ...
Full textLink to itemCite
Journal ArticleJAMA Ophthalmol · January 1, 2019
IMPORTANCE: Moderate to substantial agreement between Early Treatment Diabetic Retinopathy Study (ETDRS) 7-field imaging and ultrawide-field (UWF) imaging has been suggested in single-center studies. Comparing images obtained by multiple centers could incr ...
Full textLink to itemCite
Journal ArticleOphthalmology · December 2018
PURPOSE: To analyze the prevalence, incidence, and clinical characteristics of eyes with geographic atrophy (GA) in age-related macular degeneration (AMD), including clinical and genetic factors affecting enlargement. DESIGN: Prospective cohort study withi ...
Full textLink to itemCite
Journal ArticleJAMA Ophthalmol · October 1, 2018
IMPORTANCE: Ranibizumab is a viable treatment option for eyes with proliferative diabetic retinopathy (PDR) through 2 years. However, longer-term results are needed. OBJECTIVE: To evaluate efficacy and safety of 0.5-mg intravitreous ranibizumab vs panretin ...
Full textLink to itemCite
Journal ArticleOphthalmology · July 2018
PURPOSE: To assess systemic vascular endothelial growth factor (VEGF)-A levels after treatment with intravitreous aflibercept, bevacizumab, or ranibizumab. DESIGN: Comparative-effectiveness trial with participants randomly assigned to 2 mg aflibercept, 1.2 ...
Full textLink to itemCite
ConferenceJAMA Ophthalmol · April 1, 2018
IMPORTANCE: Comparisons of monthly vs treat-and-extend anti-vascular endothelial growth factor (anti-VEGF) regimens for macular edema from central retinal vein occlusion or hemiretinal vein occlusion is needed. OBJECTIVE: To compare visual acuity letter sc ...
Full textLink to itemCite
Journal ArticleRetina · February 2018
PURPOSE: To explore a possible association between full-field electroretinograms with vitreomacular adhesion resolution and best-corrected visual acuity as part of the prospective, randomized, double-masked, sham-controlled Ocriplasmin for Treatment for Sy ...
Full textLink to itemCite
Journal ArticleJAMA Ophthalmol · January 1, 2018
IMPORTANCE: Some eyes have persistent diabetic macular edema (DME) following anti-vascular endothelial growth factor (anti-VEGF) therapy for DME. Subsequently adding intravitreous corticosteroids to the treatment regimen might result in better outcomes tha ...
Full textLink to itemCite
Journal ArticlePDA J Pharm Sci Technol · 2018
PURPOSE: A ranibizumab prefilled syringe (PFS) has been approved by the U.S. Food and Drug Administration. Here we evaluate the use of the ranibizumab PFS for intravitreal injection by assessing whether the PFS enables healthcare providers to successfully ...
Full textLink to itemCite
Journal ArticleJAMA Ophthalmol · June 1, 2017
IMPORTANCE: Macular edema (ME) is the leading cause of decreased visual acuity (VA) associated with retinal vein occlusion (RVO). Identifying factors associated with better outcomes in RVO eyes treated with anti-vascular endothelial growth factor (VEGF) th ...
Full textLink to itemCite
Journal ArticleJAMA Ophthalmol · February 2016
IMPORTANCE: Comparisons of the relative effect of 3 anti-vascular endothelial growth factor agents to treat diabetic macular edema warrant further assessment. OBJECTIVE: To provide additional outcomes from a randomized trial evaluating 3 anti-vascular endo ...
Full textLink to itemCite
Journal ArticleJAMA · November 24, 2015
IMPORTANCE: Panretinal photocoagulation (PRP) is the standard treatment for reducing severe visual loss from proliferative diabetic retinopathy. However, PRP can damage the retina, resulting in peripheral vision loss or worsening diabetic macular edema (DM ...
Full textLink to itemCite
Journal ArticleBMC Ophthalmol · October 30, 2015
BACKGROUND: Dexamethasone intravitreal implant 0.7 mg (DEX 0.7) was approved for treatment of diabetic macular edema (DME) after demonstration of its efficacy and safety in the MEAD registration trials. We performed subgroup analysis of MEAD study results ...
Full textLink to itemCite
Journal ArticleOphthalmology · September 2015
PURPOSE: To evaluate the association of subretinal hyperreflective material (SHRM) with visual acuity (VA), geographic atrophy (GA), and scar in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). DESIGN: Prospective cohort study w ...
Full textLink to itemCite
Journal ArticleOphthalmology · September 2015
PURPOSE: To evaluate the association of subretinal hyperreflective material (SHRM) with visual acuity (VA), geographic atrophy (GA), and scar in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). DESIGN: Prospective cohort study w ...
Full textLink to itemCite
Journal ArticleJAMA Ophthalmol · August 2015
IMPORTANCE: Optimization of glycemic control is critical to reduce the number of diabetes mellitus-related complications, but long-term success is challenging. Although vision loss is among the greatest fears of individuals with diabetes, comprehensive per ...
Full textLink to itemCite
Journal ArticleN Engl J Med · March 26, 2015
BACKGROUND: The relative efficacy and safety of intravitreous aflibercept, bevacizumab, and ranibizumab in the treatment of diabetic macular edema are unknown. METHODS: At 89 clinical sites, we randomly assigned 660 adults (mean age, 61±10 years) with diab ...
Full textLink to itemCite
Journal ArticleN Engl J Med · March 26, 2015
BACKGROUND: The relative efficacy and safety of intravitreous aflibercept, bevacizumab, and ranibizumab in the treatment of diabetic macular edema are unknown. METHODS: At 89 clinical sites, we randomly assigned 660 adults (mean age, 61±10 years) with diab ...
Full textLink to itemCite
Journal ArticleJAMA Ophthalmol · February 2014
IMPORTANCE: The Age-Related Eye Disease Study (AREDS) formulation for the treatment of age-related macular degeneration (AMD) contains vitamin C, vitamin E, beta carotene, and zinc with copper. The Age-Related Eye Disease Study 2 (AREDS2) assessed the valu ...
Full textLink to itemCite
Journal ArticleJ Biomed Opt · January 2014
Vitreoretinal surgery is performed using mechanical dissection that sometimes results in iatrogenic complications, including vitreous hemorrhage, retinal breaks, incomplete membrane delamination, retinal distortion, microscopic damage, etc. An ultraprecise ...
Full textLink to itemCite
Journal ArticleJAMA Ophthalmol · July 2013
IMPORTANCE: Age-related cataract is a leading cause of visual impairment in the United States. The prevalence of age-related cataract is increasing, with an estimated 30.1 million Americans likely to be affected by 2020. OBJECTIVE: To determine whether dai ...
Full textLink to itemCite
Journal ArticleJAMA Ophthalmol · July 2013
IMPORTANCE: Age-related cataract is a leading cause of visual impairment in the United States. The prevalence of age-related cataract is increasing, with an estimated 30.1 million Americans likely to be affected by 2020. OBJECTIVE: To determine whether dai ...
Full textLink to itemCite
ConferenceProgress in Biomedical Optics and Imaging - Proceedings of SPIE · June 7, 2013
Vitreoretinal surgery is performed using mechanical dissection that sometimes results in iatrogenic complications, including vitreous hemorrhage, retinal breaks, incomplete membrane delamination, retinal distortion, microscopic damage, etc. The laser probe ...
Full textCite
Journal ArticleJAMA · May 15, 2013
IMPORTANCE: Oral supplementation with the Age-Related Eye Disease Study (AREDS) formulation (antioxidant vitamins C and E, beta carotene, and zinc) has been shown to reduce the risk of progression to advanced age-related macular degeneration (AMD). Observa ...
Full textLink to itemCite
ConferenceProgress in Biomedical Optics and Imaging - Proceedings of SPIE · June 13, 2012
Ophthalmic surgery may benefit from the use of more precise fiber delivery systems for laser surgery. In this study, chains of sapphire microspheres integrated into the distal tip of a hollow waveguide are used for preliminary midinfrared, Erbium:YAG laser ...
Full textCite
Journal ArticleJ Biomed Opt · June 2012
Ophthalmic surgery may benefit from use of more precise fiber delivery systems during laser surgery. Some current ophthalmic surgical techniques rely on tedious mechanical dissection of tissue layers. In this study, chains of sapphire microspheres integrat ...
Full textLink to itemCite
Journal ArticleOphthalmology · June 2012
OBJECTIVE: To evaluate the long-term safety and efficacy of multiple intravitreal ranibizumab injections (Lucentis, Genentech, Inc., South San Francisco, CA) administered at the investigator's discretion in patients with choroidal neovascularization second ...
Full textLink to itemCite
Journal ArticleEye (Lond) · June 2012
PURPOSE: To determine the rate of progression of eyes with subclinical diabetic macular edema (DME) to clinically apparent DME or DME necessitating treatment during a 2-year period. METHODS: In all, 43 eyes from 39 study participants with subclinical DME, ...
Full textLink to itemCite
Journal ArticleEye (Lond) · June 2012
PURPOSE: To determine the rate of progression of eyes with subclinical diabetic macular edema (DME) to clinically apparent DME or DME necessitating treatment during a 2-year period. METHODS: In all, 43 eyes from 39 study participants with subclinical DME, ...
Full textLink to itemCite
Journal ArticleRetina · June 2011
PURPOSE: To evaluate 14-week effects of intravitreal ranibizumab or triamcinolone in eyes receiving focal/grid laser for diabetic macular edema and panretinal photocoagulation. METHODS: Three hundred and forty-five eyes with a visual acuity of 20/320 or be ...
Full textLink to itemCite
ConferenceProceedings of SPIE - The International Society for Optical Engineering · April 22, 2011
The effects of periodical focusing of light were studied in chains of sapphire microspheres with 300 μm diameters assembled either on a substrate or inside capillary tubing. Dye-doped fluorescent microspheres were used as multimodal sources of light in exp ...
Full textCite
Journal ArticleOpt Express · February 14, 2011
Focusing of multimodal beams by chains of dielectric microspheres assembled directly inside the cores of hollow waveguides is studied by using numerical ray tracing. The device designs are optimized for laser surgery in contact mode with strongly absorbing ...
Full textLink to itemCite
ConferenceProceedings of SPIE - The International Society for Optical Engineering · May 3, 2010
Integration of microspheres inside micro-capillaries or hollow waveguides may allow development of compact focusing tools for a variety of biomedical and photonics applications. However, problems associated with developing focusing microprobes involve the ...
Full textCite
Journal ArticleAm J Ophthalmol · November 2009
PURPOSE: To evaluate the incidence of intravitreal silicone oil (SO) droplets associated with intravitreal injections using a staked-on vs luer cone syringe design in the SCORE (Standard Care vs COrticosteroid in REtinal Vein Occlusion) Study. DESIGN: Pros ...
Full textLink to itemCite
Journal ArticleOphthalmology · September 2009
OBJECTIVE: To describe the baseline characteristics of the participants in the Standard Care versus COrticosteroid for REtinal Vein Occlusion (SCORE) Study and to compare with cohorts from other retinal vein occlusion trials. The design of the SCORE Study ...
Full textLink to itemCite
Journal ArticleArch Ophthalmol · September 2009
OBJECTIVE: To describe characteristics of the Age-Related Eye Disease Study (AREDS) 9-step severity scale applied to participants in the Complications of Age-related Macular Degeneration Prevention Trial (CAPT). METHODS: Eligibility criteria for CAPT requi ...
Full textLink to itemCite
Journal ArticleArch Ophthalmol · April 2009
OBJECTIVE: To assess changes in electroretinography (ERG) and other retinal function parameters during 6 months of daily use of tadalafil, sildenafil citrate, or placebo. METHODS: Subjects were randomized to use of a placebo (n=82), 5 mg of tadalafil (n=85 ...
Full textLink to itemCite
Journal ArticleArch Ophthalmol · February 2009
OBJECTIVE: To compare the effects of single-sitting vs 4-sitting panretinal photocoagulation (PRP) on macular edema in subjects with severe nonproliferative or early proliferative diabetic retinopathy with relatively good visual acuity and no or mild cente ...
Full textLink to itemCite
Journal ArticleOphthalmology · November 2008
OBJECTIVE: To describe baseline night vision symptoms and their association with >/=3-lines loss in visual acuity (VA), choroidal neovascularization (CNV), and geographic atrophy (GA). DESIGN: Cohort study within a multicenter randomized clinical trial. PA ...
Full textLink to itemCite
Journal ArticleAm J Ophthalmol · May 2008
PURPOSE: To evaluate optical coherence tomography (OCT) thickness of the macula in people with diabetes but minimal or no retinopathy and to compare these findings with published normative data in the literature from subjects reported to have no retinal di ...
Full textLink to itemCite
Journal ArticleAm J Ophthalmol · May 2008
PURPOSE: To assess the efficacy and adverse-events profile of combined treatment with ranibizumab and verteporfin photodynamic therapy (PDT) in patients with predominantly classic choroidal neovascularization (CNV) secondary to neovascular age-related macu ...
Full textLink to itemCite
Journal ArticleRetina · 2008
PURPOSE: To compare baseline demographic, systemic, and ocular characteristics within age and racial subgroups among participants in this Diabetic Retinopathy Clinical Research Network clinical trial and to compare this cohort with other cohorts enrolled i ...
Full textLink to itemCite
ConferenceOphthalmology · March 2007
OBJECTIVE: To compare optical coherence tomography (OCT)-measured retinal thickness and visual acuity in eyes with diabetic macular edema (DME) both before and after macular laser photocoagulation. DESIGN: Cross-sectional and longitudinal study. PARTICIPAN ...
Full textLink to itemCite
ConferenceOphthalmology · March 2007
OBJECTIVE: To compare optical coherence tomography (OCT)-measured retinal thickness and visual acuity in eyes with diabetic macular edema (DME) both before and after macular laser photocoagulation. DESIGN: Cross-sectional and longitudinal study. PARTICIPAN ...
Full textLink to itemCite
Journal ArticleOphthalmology · February 2007
OBJECTIVE: An examination of clinically relevant subgroups of patients in the MARINA study of ranibizumab in treatment of minimally classic or occult with no classic choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) was ...
Full textLink to itemCite
Journal ArticleArch Ophthalmol · December 2006
OBJECTIVE: To evaluate diurnal variation in retinal thickness measured with optical coherence tomography (OCT) in patients with center-involved diabetic macular edema. METHODS: Serial OCT3 measurements were performed in 156 eyes of 96 subjects with clinica ...
Full textLink to itemCite
Journal ArticleArch Ophthalmol · December 2006
OBJECTIVE: To evaluate diurnal variation in retinal thickness measured with optical coherence tomography (OCT) in patients with center-involved diabetic macular edema. METHODS: Serial OCT3 measurements were performed in 156 eyes of 96 subjects with clinica ...
Full textLink to itemCite
Journal ArticleOphthalmology · November 2006
OBJECTIVE: To evaluate the efficacy and safety of low-intensity laser treatment in the prevention of visual acuity (VA) loss among participants with bilateral large drusen. DESIGN: Multicenter randomized clinical trial. One eye of each participant was assi ...
Full textLink to itemCite
Journal ArticleOphthalmology · November 2006
OBJECTIVE: To evaluate the efficacy and safety of low-intensity laser treatment in the prevention of visual acuity (VA) loss among participants with bilateral large drusen. DESIGN: Multicenter randomized clinical trial. One eye of each participant was assi ...
Full textLink to itemCite
Journal ArticleOphthalmology · April 2006
OBJECTIVE: To assess safety of repeated intravitreal injections of ranibizumab in treating neovascular age-related macular degeneration (AMD), and to assess changes in visual acuity (VA) and AMD lesion characteristics. DESIGN: Multicenter, controlled, open ...
Full textLink to itemCite
Journal ArticleOphthalmology · July 2004
OBJECTIVE: To describe characteristics of participants in the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT) at baseline and to investigate associations among visual function, fundus features, and vision-related quality of life. ...
Full textLink to itemCite
Journal ArticleOphthalmology · July 2004
OBJECTIVE: To describe characteristics of participants in the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT) at baseline and to investigate associations among visual function, fundus features, and vision-related quality of life. ...
Full textLink to itemCite
Journal ArticleAm J Ophthalmol · May 2003
PURPOSE: To report a side effect of transpupillary thermotherapy for choroidal melanoma. DESIGN: Small case series. METHODS: Review of clinical charts and photographs in a private retina practice. RESULTS: Retinal tears developed in two patients after tran ...
Full textLink to itemCite
Journal ArticleOphthalmology · February 1999
OBJECTIVE: To determine the effect of the surgeon and the wavelength of laser used on the response to focal photocoagulation for diabetic macular edema. DESIGN: Retrospective case-control study. PARTICIPANTS: Forty-four matched pairs of cases by two differ ...
Full textLink to itemCite
Journal ArticleOphthalmology · April 1998
OBJECTIVE: This study aimed to test the efficacy and safety of laser chorioretinal anastomosis for central retinal vein occlusion (CRVO). DESIGN: The study design was a consecutive case series. PARTICIPANTS: Eight eyes of eight patients were treated. INTER ...
Full textLink to itemCite
Journal ArticleGraefes Arch Clin Exp Ophthalmol · 1993
Corticosteroids, alone or in combination with other drugs, have been shown to inhibit angiogenesis. The purpose of this study was to evaluate the efficacy of triamcinolone acetonide in a new model of preretinal neovascularization. Rabbit eyes were treated ...
Full textLink to itemCite
Journal ArticleOphthalmology · May 1992
Photic retinal injuries have been described after surgical exposure to the intense illumination systems of operating microscopes. The overall incidence of such injuries has been postulated at less than 10%. The authors prospectively studied 43 consecutive ...
Full textLink to itemCite
Journal ArticleInvest Ophthalmol Vis Sci · January 1991
Although progressive retinal neovascularization is a potentially blinding complication of several diseases, there are no good animal models. The authors developed a consistent model of preretinal neovascularization in the rabbit by partially digesting the ...
Link to itemCite
Journal ArticleInvest Ophthalmol Vis Sci · November 1990
The authors previously developed a new model of preretinal neovascularization in the rabbit eye using hyaluronidase for enzymatic vitreolysis. The purpose of this study was to evaluate the safety of intravitreal injections of hyaluronidase. Concentrations ...
Link to itemCite
Journal ArticleAm J Ophthalmol · May 15, 1989
In 42 cases of complicated retinal detachment following trauma after failed primary vitrectomy, at six months follow-up anatomic retinal reattachment posterior to the scleral buckle was achieved in 20 of 40 eyes (50%). Of the 40 eyes, 11 (28%) had a visual ...
Full textLink to itemCite
Journal ArticleOphthalmology · April 1986
Numerous complications resulting from retrobulbar injections in the injected eye and orbit have been reported. A rare complication of retrobulbar anesthesia is the occurrence of decreased visual acuity and extraocular muscle palsies in the contralateral ey ...
Full textLink to itemCite